Australia's most trusted
source of pharma news
Monday, 27 July 2026
Posted 27 July 2026 AM
AstraZeneca was the leading performer in 2025, securing more PBAC recommendations than any other pharmaceutical company while Celltrion Healthcare, Novartis, and Roche finished in a tie for second place.
Not only did AstraZeneca score the greatest number of recommendations at 10 but it has already achieved a PBS listing for nine, including two new treatments – breast cancer drug Truqap and injectable asthma drug Tezspire.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.